diagnost anim health
blood analyz blood test veterinarian
client offer wide rang chemistri
hematolog immunotherapi test
high-definit digit radiographi
digit ultrasound technolog pair
requir disclosur end report
view current cl king meet event calendar coverag univers
calendar
host analyst day tomorrow new york citi analyst day
expect provid new product updat idea geograph
expans invest exactli look
gain follow miss well price stock
thesi done admir job go
market share compani longer
obscur player anim health ah space
face player view competit threat reiter neutral rate
get construct month ago biggest concern
estim high percept new product would drive back
half growth sinc compani wide miss guid well
expect push back timelin new product geograph
expans stock appreci happi
expect reset realli like direct ceo kevin wilson
taken compani believ current valuat give
new product new product shouldnt complet surpris competitor
product current product bag would like
highest roi includ urin analysi urin sediment analysi
rapid assay test less like candid includ practic
manag softwar new analyz new imag equip
geograph expans europ like market geograph
expans though competitor pretti good traction australia
asia well henri schein nr distributor deepest
traction europ best partner view cours
manag channel conflict sinc henri schein
analyz also sell abaxi abaxa hasnt problem
 fact check suggest schein rep prefer sell
equip though schein diagnost brand scil decent
traction europ
trend idexx idxxa revenu
come abroad abaxi vs contrari mani
investor expect intern revenu grew compound
annual rate traction
abroad new concept compani sale infrastructur
salesforc expans competitor ramp salesforc
significantli last coupl quarter surpris
increas sale coverag begin
abaxi field rep three week ago
process ad farmer defend account note
sale personnel last though number like includ
field rep
model fine-tun model shift revenu tougher comp
easier comp new estim see lower revenu
ep fall slightli rais full-
year estim still tad
consensu keep ep estim
maintain revenu estim lower ep
reflect anticip invest discuss
analyst day alreadi new product contribut model
introduc revenu estim ep
pioneer new market product expens intens though
reward high attest compani growth last
quarter alreadi larg revenu base given cost pioneer
new market like product creat
exist user like product rapid test urin sediment analyz
urin chemistri analyz three rapid multiplex market
largest peg idexx revenu around though
remind investor heartworm test rapid
addit rapid test would increment heska
understand vs extern develop dynam
reli extern parti develop major new product
isnt uncommon veterinari medicin notabl product includ
idexx sedivu abaxi hematolog machin promin
exampl extern acquir product one differ rel
group howev chemistri machin profit
instrument manufactur design third parti fuji
nr advantag disadvantag posit side heska
inherit effort larg multi-national corpor
neg side share econom develop spend
essenti becom retail rather wholesaler/manufactur
compani anim health develop product typic use three
method develop product in-hous take exist human
product modifi anim health third parti
manufactur product modifi anim health
 dollar spent case first dollar
spent throughout process compani frequent use
method frankli afford high-risk/high-reward
method latter two method still requir dollar money
spent end process make product anim health capabl mani
time modif requir softwar updat paramet
chang move product human anim health typic
requir plu number addit debug step product
manufactur third parti case third-parti develop
compani would test run intern make sure product work properli
page
abaxi urin sediment analyz compani modest
spend work third parti develop instrument
toward end process ad proprietari featur
potenti product depth
test defin rapid test infecti diseas test perform
point care common rapid test heartworm howev lyme
felv-fiv anaplasma ehrlichia parvo also common although
technolog littl bit advanc rapid test essenti similar
form factor function seen pregnanc test plastic encas strip
bodili fluid react chemic line mean posit
line mean neg peg global rapid market rapid test
pretti strong market posit estim
zoeti abaxi done great job win market
share last coupl year like far behind categori
revenu potenti well
experi product categori even attempt produc
lyme ehrlichia anaplasma singl test past delay
year rapid product go fda approv process
obviou heska name spend compani
yet fulli commit fund large-scal rapid test effort
develop rapid test think project would cost million like take
littl year approxim abaxi timelin though
sure rapid test would pursu much effort made
develop multiplex rapid full suit similar zoeti
abaxi would like take coupl million would take littl
market size henri schein would access
 veterinari clinic weve note wvc note anim
veterinarian tend order rapid test way
order basic product assum goe four
common pathogen add lyme ehrlichia anaplasma heartworm
franchis think could see penetr test
first year ad sub-seg rapid test would impli
addit revenu assum multipl rapid
test market
urin chemistri although huge market urin chemistri fairli
develop market instrument typic cost less even
compani sold instrument clinic would still
market howev instrument consum strip
sold coupl dollar per use abaxi peg urin chemistri
busi potenti growth rate veterinari diagnost
rate per annum launch urin sediment
analyz think urin chemistri analyz would natur complement
urin chemistri lack larg market potenti could make
type product would like requir spend money
veterinaz like requir softwar potenti differ
reagent like dozen compani urin chemistri
analyz human side roch rog vtx nr siemen sie
nr come mind far know type product would also avoid
page
requir fda clinic trial veterinari think urin chemistri
market opportun could add per annum
urin sediment urin sediment bigger market market in-hous
urin sediment current run rate though market could
grow much larger abaxi chang current market
dynam date urin sediment analyz place
penetr rate current placement rate
per year market pioneer well current rate
like twice size time enter wed guess
two current player use two differ approach bring product
market wait first human medicin player creat point-of-
care analyz licens instrument hungarian compani call
elektronika abaxi face choic wait second human
medic compani creat urin sediment analyz decid find third-
parti produc creat one develop advertis prototyp
market took littl year first quarter saw good traction unit
though level traction remain seen abaxi market product
full year prior launch
think like use abaxi approach think supplier would
like come asia abaxi experi clear product
would requir meaning invest although compani design
product could take care behalf intern team
need provid veterinari market insight support process
market note previous current market in-clin urin test
could grow quit significantli clinic move
manual test send refer lab autom process accord
idexx sedivu asp price abaxi
like sell product consum side use pay-
per-run model abaxi sell clean solut consum model
abaxi urin sediment first year full year
reason think could littl one-third abaxi could
first year
fecal test accord fecal antigen parasit worm test took
almost decad develop check consult suggest ip
around idexx test strong although imposs could
develop fecal antigen test worm wed expect see
beyond launch think like fecal test product would
parvo giardia could see work fecal worm float assist test
similar nr paratest test could see
signific traction would also compet manual side process
cost penni said there signific room increas complianc
fecal test market could well grow significantli
softwar repres market although huge market
put primari predict might put odd
partner schein share practic manag
softwar recent announc merger vetsfirstchoic
page
instrument integr schein core offer avimark
still mark guess own practic manag
incred import quit difficult practic switch
expans could great increment revenu stream though
would requir invest gener revenu aboard
though primarili via sell distributor
figur heska revenu geographi
term sell aboard see follow issu first could use
subscript model abroad discuss year ago
subscript model would requir strong contract legal system recal
reset model requir six-year commit pretti sever penalti
vet reneg contract addit would need add
distribut capabl fulli servic market least contract
law sort logist issu suppli would breach
end contract word enforc contract
complet fulfil end contract give veterinarian
suppli need
intern market look appeal told us past
germani appeal countri contract logist point
view also larg market offic switzerland
could act good base consolid veterinari market
world could make market address final contact
close mar said look rapidli consolid european
market gener could also facilit player
page
although p/ ev/sal basi trade discount peer
vs abaxi cheap stock fact
trade premium abaxi ev/ebitda price-to-earnings despit fact
abaxi higher growth trajectori composit abaxi revenu
also much attract higher percentag revenu recur
revenu product imag manufactur product
much higher percent sale higher-margin product
figur valuat compar abaxi use consensu estim
investor expect one biggest concern regard
stock expect around timelin new product
spent last coupl year hard think
compani anyth late stage pipelin even middl stage
develop product take time requir invest manag
number investor spoke expect prior
recent confer call launch new product
surpris lack downward stock action chang product
stock behavior last year estim fallen significantli
yet stock actual risen year ago consensu model
revenu vs today revenu estim come
sinc march yet stock flat
march
figur chang consensu estim
understand stock behavior stock isnt anomal
tax reform industry-specif fact one doesnt even
need look competitor abaxi see someth similar
abaxi stock sinc march yet estim essenti flat
overal think two forc work take specul idexx
provid umbrella valuat
attract takeout asset though think provid floor
rather specif upsid convers potenti acquir
weve found price-sensit like candid view
zoeti elanco part nr understand
page
compani would like extend diagnost capabl
use roi model develop intern vs acquir price
abaxi trade opinion zoeti elanco would prefer
develop asset use exist capabl rather spend
massiv amount requir purchas abaxi
primari asset would acquir would custom base custom list
suppli contract fuji salesforc
risk includ relianc distributor regul multipl sole supplier
vet industri macro situat price concess competit addit
think abaxi could acquir zoeti elanco
page
